Preprint · CC-BY
via OpenAlex
Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex
Aging · 2011 · ▲ 26 citations
Abstract
mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">Rapamycin(definition) inhibits the mTOR (target of rapamycin) pathway and extends lifespan in multiple species. The tuberous sclerosis complex (TSC) protein is a negative regulator of mTOR. In humans, loss of the TSC protein results in a disorder characterized clinically by the growth of benign tumors in multiple organs, due to overactivation of mTOR inhibition. Subependymal giant cell astrocytomas (SEGAs) are benign brain tumors associated with TSC that have traditionally been treated by surgery, but for which mTOR inhibitors have recently been suggested as potential alternative treatments. The duration of mTOR treatment for SEGAs might have to be prolonged, probably lifelong, because SEGAs usually grow back after treatment is stopped. This cohort of patients who will experience prolonged exposure to mTOR inhibitors should be carefully followed longitudinally to better document long term side effects, but also to compare their longevity with the one of similar patients with TSC. These patients represent a unique opportunity to study the potential anti-aging properties of mTOR inhibitors in humans.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.18632/aging.100298
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
Major, P. (2011). Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. <em>Aging</em>. https://doi.org/10.18632/aging.100298
Vancouver
Major P. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. Aging. 2011. doi:10.18632/aging.100298.
BibTeX
@unpublished{philippe2011Potent,
title = {Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex},
author = {Philippe Major},
journal = {Aging},
year = {2011},
doi = {10.18632/aging.100298},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Ottawa Hospital Research Institute 2002
Open access · US-GOV
Frailty and Postoperative Outcomes After Emergency General Surgery
Autophagy 2023
Preprint · OA
Rapamycin and Alzheimer disease: a hypothesis for the effective use of rapamycin for treatment of neurodegenerative disease
Springer eBooks 2018
Citation only
Inhibition of mTOR Signalling: A Potential Anti-aging Drug Strategy
Neuroscience 2016
Open access · CC-BY
Molecular neurobiology of mTOR
Journal of Molecular Biology 2002
Open access · OA
α-Synuclein, Especially the Parkinson's Disease-associated Mutants, Forms Pore-like Annular and Tubular Protofibrils
Springer eBooks 2020
Citation only